Abstract
Schizophrenia and other psychiatric disorders are generally diagnosed based on a collection of symptoms defined by a combination of an individual’s feelings, perceptions, and behaviors. Many of these disorders are characterized by specific cognitive and social deficits. Although it is nearly impossible to recapitulate the full phenotypic spectrum of schizophrenia in mice, mouse models play an indispensable role in understanding the pathogenesis of this disorder and the development of new therapeutics. Genetic mouse models of schizophrenia and mouse behavioral tests provide a feasible approach for elucidating causal relationships between susceptibility gene(s) and schizophrenia-related symptoms. There has been a proliferation of studies characterizing basic behavioral phenotypes in mice. Since there is no way to completely model human psychiatric symptoms in mice, the major role of behavioral tests is to provide insights into underlying affected circuitry and pathophysiology. Given that the recovery of cognitive and social abilities significantly benefits functional outcomes, there has been an increasing interest in characterizing cognitive and social functions in mutant mice; however, these functions are not easy to measure. In this review, a selection of conventional behavioral tasks was briefly described and three specific behavioral tasks aimed at characterizing social communication, attentional function, and choice behavior in mice were highlighted. The choice of specific behavioral tasks during experimental planning should take into consideration a variety of factors, including their validity, reliability, sensitivity, utility, and specificity. Based upon the hypothetical hypofunction of N-methyl-D-aspartate receptor (NMDAR)-mediated signaling pathways in the involvement of cognitive and social impairments in schizophrenia, three NMDAR-related compounds/drugs, D-serine, sarcosine, and D-cycloserine, are discussed as an example.
Keywords: Schizophrenia, mouse behavioral tasks, cognitive/social deficit, social communication, attention, choice behavior, glutamate hypothesis of schizophrenia, glycine.
Current Pharmaceutical Design
Title:Assessing Schizophrenia-relevant Cognitive and Social Deficits in Mice: A Selection of Mouse Behavioral Tasks and Potential Therapeutic Compounds
Volume: 20 Issue: 32
Author(s): Wen-Sung Lai, Chia-Yuan Chang, Wan-Rong Wong, Ju-Chun Pei, Ya-Shan Chen and Wei-Li Hung
Affiliation:
Keywords: Schizophrenia, mouse behavioral tasks, cognitive/social deficit, social communication, attention, choice behavior, glutamate hypothesis of schizophrenia, glycine.
Abstract: Schizophrenia and other psychiatric disorders are generally diagnosed based on a collection of symptoms defined by a combination of an individual’s feelings, perceptions, and behaviors. Many of these disorders are characterized by specific cognitive and social deficits. Although it is nearly impossible to recapitulate the full phenotypic spectrum of schizophrenia in mice, mouse models play an indispensable role in understanding the pathogenesis of this disorder and the development of new therapeutics. Genetic mouse models of schizophrenia and mouse behavioral tests provide a feasible approach for elucidating causal relationships between susceptibility gene(s) and schizophrenia-related symptoms. There has been a proliferation of studies characterizing basic behavioral phenotypes in mice. Since there is no way to completely model human psychiatric symptoms in mice, the major role of behavioral tests is to provide insights into underlying affected circuitry and pathophysiology. Given that the recovery of cognitive and social abilities significantly benefits functional outcomes, there has been an increasing interest in characterizing cognitive and social functions in mutant mice; however, these functions are not easy to measure. In this review, a selection of conventional behavioral tasks was briefly described and three specific behavioral tasks aimed at characterizing social communication, attentional function, and choice behavior in mice were highlighted. The choice of specific behavioral tasks during experimental planning should take into consideration a variety of factors, including their validity, reliability, sensitivity, utility, and specificity. Based upon the hypothetical hypofunction of N-methyl-D-aspartate receptor (NMDAR)-mediated signaling pathways in the involvement of cognitive and social impairments in schizophrenia, three NMDAR-related compounds/drugs, D-serine, sarcosine, and D-cycloserine, are discussed as an example.
Export Options
About this article
Cite this article as:
Lai Wen-Sung, Chang Chia-Yuan, Wong Wan-Rong, Pei Ju-Chun, Chen Ya-Shan and Hung Wei-Li, Assessing Schizophrenia-relevant Cognitive and Social Deficits in Mice: A Selection of Mouse Behavioral Tasks and Potential Therapeutic Compounds, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612819666140110122750
DOI https://dx.doi.org/10.2174/1381612819666140110122750 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Nitric Oxide’s Involvement in the Spectrum of Psychotic Disorders
Current Medicinal Chemistry Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice
Current Alzheimer Research The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Screening for Amyloid Aggregation: In-Silico, In-Vitro and In-Vivo Detection
Current Protein & Peptide Science 5-Hydroxymethylfurfural (HMF) in Organic Synthesis: A Review of its Recent Applications Towards Fine Chemicals
Current Organic Synthesis Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Letters in Drug Design & Discovery Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets